Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
OKLAHOMA CITY, Oct. 25, 2017 -- Federman & Sherwood announces that on October 23, 2017, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Antares Pharma, Inc. (NASDAQ:ATRS). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is December 21, 2016 through October 12, 2017.
Plaintiff seeks to recover damages on behalf of all Antares Pharma, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Friday, December 22, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: [email protected]
Or, visit the firm’s website at www.federmanlaw.com
